NCT06010303 2025-11-17
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07019181 2025-06-13
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT06965829 2025-05-11
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06914687 2025-04-06
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06692270 2025-02-28
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06430658 2024-12-27
NEXUS-2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06646588 2024-10-17
SJZ-RMEEC01
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT04776590 2024-04-12
CRISEC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Active not recruiting
NCT06061146 2023-12-26
TCRTOE
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting